USPTO serial 79115013
THIOLOGICS
Reviewed by CopyMark Law Group
Reg. 4452854Status 404
- Filing date
- Status date
- Registration date
- Dec 24, 2013
- Examiner
- TWOHIG, SHANNON MARIE
- Law office
- TMO LAW OFFICE 121
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with THIOLOGICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Joel D. Voelzke
Joel D. Voelzke IP Law Offices of Joel Voelzke, APC24772 W. Saddle Peak RoadMalibu, CA 90265UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for use in bioconjugation, reversible bioconjugation, irreversible bioconjugation, reversible cysteine protection, surface modification, and prodrug production; biochemicals, namely, polypeptides, polypeptides for in vivo applications, polypeptides for in vitro applications, polynucleic acids, polynucleic acids for in vivo applications, and polynucleic acids for in vitro applications; biomolecules, namely, proteins, peptides, antibodies, antibody fragments, antibody mimetic proteins, and polynucleic acids; chemical products for diagnostic use, namely, conjugates of polypeptides with small molecule drugs, imaging agents, and radionuclides for medical applications; biochemical preparations, namely, polypeptides, polynucleic acids, and antibodies, all for use in medical research; biochemical preparations, namely, polypeptides, polynucleic acids, and antibodies, all for use in diagnosis and treatment of disease | SECTION 71 - CANCELLED | — |
| 005 | Pharmaceutical preparations, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of autoimmune, cardiovascular, central nervous system, dental, dermatology, endocrine, gastrointestinal, genetic, hematology, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurological, oncology, ophthalmological, otolaryngology, psychiatric, respiratory, urogenital, urological and viral diseases and disorders in animals and humans; biological preparations, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of autoimmune, cardiovascular, central nervous system, dental, dermatology, endocrine, gastrointestinal, genetic, hematology, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurological, oncology, ophthalmological, otolaryngology, psychiatric, respiratory, urogenital, urological and viral diseases and disorders in animals and humans; diagnostic preparations for medical purposes; diagnostic preparations for scientific or research use; diagnostic kits consisting primarily of antibody preparations, namely, antibody bioconjugates, namely, antibody-drug conjugates, antibody-radionuclide conjugates and antibody-imaging agent conjugates for use in diagnosis and treatment of autoimmune, cardiovascular, central nervous system, dental, dermatology, endocrine, gastrointestinal, genetic, hematology, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurological, oncology, ophthalmological, otolaryngology, psychiatric, respiratory, urogenital, urological and viral diseases and disorders in animals and humans; diagnostic kits consisting primarily of chemical products for medical diagnostic use, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of autoimmune, cardiovascular, central nervous system, dental, dermatology, endocrine, gastrointestinal, genetic, hematology, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurological, oncology, ophthalmological, otolaryngology, psychiatric, respiratory, urogenital, urological and viral diseases and disorders in animals and humans; diagnostic kits consisting primarily of biochemical preparations, namely, polypeptide bioconjugates and polynucleic acid bioconjugates for use in diagnosis and treatment of autoimmune, cardiovascular, central nervous system, dental, dermatology, endocrine, gastrointestinal, genetic, hematology, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurological, oncology, ophthalmological, otolaryngology, psychiatric, respiratory, urogenital, urological and viral diseases and disorders in animals and humans | SECTION 71 - CANCELLED | — |
| 042 | Scientific and technological services, namely, design and assembly of polypeptide bioconjugates and polynucleic acid bioconjugates, and design and optimization of proprietary bioconjugation technologies; biological research; chemical research and analysis; scientific advisory services relating to research and development in the field of diagnostic preparations and diagnostic products; providing scientific information and advisory services in the fields of scientific research and design, and biological and chemical research | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by UCL Business plc
- Other trademarks owned by UCL Business plc
- Other trademarks owned by UCL Business plc
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named THIOLOGICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 21, 2022 | DENC | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Aug 21, 2022 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Jan 29, 2022 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Dec 23, 2021 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Dec 23, 2021 | INPC | INVALIDATION PROCESSED | — |
| Oct 26, 2021 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Oct 2, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 26, 2021 | C71T | CANCELLED SECTION 71 | — |
| Dec 24, 2018 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jun 6, 2014 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 19, 2014 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 19, 2014 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 24, 2014 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Dec 24, 2013 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 8, 2013 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 8, 2013 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 7, 2013 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Sep 18, 2013 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 18, 2013 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Sep 18, 2013 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 30, 2013 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Aug 22, 2013 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 20, 2013 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 20, 2013 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 20, 2013 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Mar 7, 2013 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Mar 7, 2013 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 7, 2013 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 14, 2013 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 14, 2013 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 7, 2013 | ALIE | ASSIGNED TO LIE | — |
| Feb 6, 2013 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 30, 2012 | RFNT | REFUSAL PROCESSED BY IB | — |
| Aug 7, 2012 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 7, 2012 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Aug 7, 2012 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Aug 7, 2012 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 6, 2012 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 3, 2012 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 3, 2012 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 2, 2012 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |